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Background. Lhermitte’s sign (LS) is a benign form of myelopathy with neck ﬂexion producing an unpleasant electric-shock
sensation radiating down the extremities. Although rare, it can occur after head and neck radiotherapy. Results.W er e p o r ta
case of Lhermitte’s developing after curative intensity-modulated radiotherapy (IMRT) for a patient with locoregionally advanced
oropharyngealcancer.IMRTdeliversaconformaldoseofradiationinheadandneckcancerresultinginagradientofradiationdose
throughout the spinal cord. Using IMRT, more dose is delivered to the anterior spinal cord than the posterior cord. Conclusions.
Lhermitte’ssigncan develop after IMRTforhead and neck cancer. Weproposean anteriorspinalcord structure,thespinothalamic
tract to be the target of IMRT-caused LS.
1.Introduction
Lhermitte’s sign (LS) was ﬁrst observed in patients with
multiple sclerosis by Marie and Chatelin in 1917 but it
did not get world recognition in neurology until Jean
Lhermitte published his report in 1920 and review in 1924
[1]. Lhermitte’s sign is an electric shock-like sensation
manifesting from the nape of the neck to the tips of the limbs
by ﬂexing the head forward. In general, it is a benign form
of myelopathy without any permanent damage to the spinal
cord.ThesymptomsofLSusuallybeginwithinafewmonths
of completion of radiotherapy and are transient. This is
in contrast to radiation myelitis where symptoms generally
develop one year or more after radiation and progress to
permanent spinal cord injury. The development of LS does
not predict the development of radiation myelitis. Though
LS is considered to be a classic sign of multiple sclerosis, it
has been observed in patients with other conditions [2].
Lhermitte’s sign has been known to be a side eﬀect of
radiotherapy (RT) of head and neck cancer patients who
have received radiation to the cervical spinal cord (CSC) [3].
With the introduction of Intensity-Modulated Radiotherapy
(IMRT), radiation oncologists have been able to deliver
more conformal radiation to head and neck tumors. Such
conformal radiotherapy should allow less radiation to the
spinal cord. Although there have been cases of LS in patients
with head and neck cancer receiving non-IMRT, there have
been no published reports of LS in patients with head and
neck cancer treated with IMRT.
We report a case of Lhermitte’s sign developing in a
patient with locoregionally advanced oropharyngeal squa-
mous cell carcinoma treated successfully with concurrent
chemotherapy and IMRT.
2.CaseReport
Our patient is a 55-year-old gentleman with a clinical
s t a g eT 2 N 2 Am o d e r a t et op o o r l yd i ﬀerentiated squamous
cell carcinoma of the left tonsil. He received concurrent
chemotherapy delivered during the ﬁrst and fourth weeks
of radiation treatment. The chemotherapy consisted of cis-
platin at 100mg/m2 and ﬂuorouracil (5FU) at 1000mg/m2
on days one through four. We used intensity-modulated2 International Journal of Otolaryngology
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Figure 1: Radiation dose distribution as represented by radiation isodose lines displayed in the (a) axial, (b) sagittal, and (c) coronal planes.
The thick purple line represents the 4500 cGy isodose line. The dose volume histogram (d) graphs the percent volume of structure or target
receiving a radiation dose. Radiation targets including the red gross tumor volume (GTV), the beige expansion of GTV (CTV1), the yellow
high-risk clinical volume (CTV2), and light blue low-risk clinical volume (CTV3) are included with the critical normal structures of spinal
cord and brainstem.
radiotherapy with primary intent to spare the right parotid
gland. A total dose of 7000cGy was delivered to our
expandedtumortargetusing6MVphotonsover35fractions
of 200cGy each. In treatment planning, the spinal cord
was contoured. The maximum spinal cord point dose was
4478cGy and the mean spinal cord dose was 2692cGy.
Figure 1 displays radiation dose distribution throughisodose
lines in the axial, sagittal, and coronal planes as well as the
dose volume histogram (DVH) for treatment targets, the
brainstem and the spinal cord. Image guidance with orthog-
onal pair radiographs, AP and lateral, was performed prior
to each daily treatment. The patient tolerated the treatment
course fairly well with expected conﬂuent mucositis and
temporary need of a feeding tube for nutrition. The patient
lost 3.4kg (4.9% of initial body weight) throughout the
treatment, going from 69.2kg to 65.9kg at the completion of
treatment on May 19, 2006; the patient showed no evidence
of disease.
Four months after completion of treatment, in Septem-
ber2006,thepatientﬁrstdevelopedelectric-shocksensations
with neck ﬂexion causing severe right arm pain with the
feeling that the extremity was swollen and numb. The
severity of the pain prompted an ER visit. On the patient’s
followupinOctober,thepatienthadpersistentdiﬃcultywith
these electric-shock sensations radiating down his back into
his arms with neck ﬂexion. The patient experienced another
episodeinNovembertotheleftforearmrequiringoxycodone
to alleviate the pain. When the patient came for followupInternational Journal of Otolaryngology 3
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Figure 2: Radiation dose distribution represented by radiation isodose lines through an axial plane of the cervical spinal cord. (a) Dose
distribution with IMRT and (b) dose distribution using a non-IMRT plan using opposed lateral beams. The light blue line represents the
4800 cGy isodose line and the purple line represents the 4500cGy isodose line.
in December, he reported no further severe painful episodes
but“occasional”shocksandnumbnessbetweenthethirdand
fourth ﬁngers on both hands. In March of 2007, the patient
had an “electric sensation” down his spine and into his jaw
that left him with diﬃculty chewing for three days. At his
June 2007 followup, the patient reported some mild ﬁnger
numbness but no persistent electric-shock sensations. At the
last followup in April 2009, the patient reported no further
symptoms and was working as a contractor/remodeler. On
physical examination, he had no neurologic deﬁcits and no
evidence of disease.
3. Discussion
Radiation to the cervical spine is a known cause of Lher-
mitte’s sign. Leung et al. report an incidence as high as 10.3%
in patients receiving non-IMRT for nasopharyngeal cancer
[3]. This incidence may be higher than that seen in other
head and neck sites due to the nature of radiotherapy for
nasopharyngeal tumors and the close proximity of disease to
thecervicalspinal cord.Feinet al.report anoverallincidence
of 3.6% of LS in 1112 patients receiving at least 30Gy to at
least 2 cm of cervical spinal cord [4]. Chemotherapy such as
cisplatin has also been reported to cause LS [5, 6], and this
may have contributed to the development of LS in our case.
Total radiation dose and fraction size may play a role in the
risk of developing LS. Fein and colleagues describe patients
receiving ≥200cGy per fraction (one fraction per day) or
≥5000cGy total dose to the CSC having an increased risk
of developing LS. Leung ﬁnds a higher incidence of LS in
patients requiring bilateral neck-boost irradiation. In these
patients, the spinal cord dose was greater than 49.8Gy and
there was an 11.5% incidence of LS. This is compared with
patients receiving no neck boost where the spinal cord dose
was 46.8Gy and the incidence of LS was 7.2%. However,
Million and Cassisi state that total spinal cord doses as low as
3000cGy with fractions sizes of 120cGy may produce mild
symptoms of LS [7]. With the introduction of IMRT, we
have been able to deliver more conformal radiation doses
to patients with head and neck cancer. We have seen 3
cases of LS develop after head and neck IMRT for 291
patients, the other two cases with much milder symptoms.
Our case report patient received a cord maximum dose of
4478cGy with 128cGy maximum dose to the cord daily.
With the conformal dose of IMRT, the mean cord dose
was only 2692cGy. In non-IMRT, opposed lateral ﬁelds are
frequently utilized resulting in a much more homogeneous
dose distribution to the spinal cord. Reviewing four studies
where patients were treated with non-IMRT, the maximum
cord dose was similar to ours at 4716 (±770cGy) but the
mean cord dose was much higher at 4026 (±425cGy) [8–
10]. Our experience of LS developing in 1% of our head and
neck IMRT cases suggests that IMRT may result in a lower
incidence of LS, certainly lower than the 10.3% reported
by Leung and colleagues and lower than the 3.6% seen by
Fein et al.
The time to development of LS in our patient of four
months after chemoradiation is similar to the time to
symptomsreportedbyFein(mean,threemonths)andLeung
(median, three months). Our patient’s symptoms lasted
approximately nine months also in line with the duration of
symptoms reported by Fein (mean, six months) and Leung
(median, seventeen weeks).
Jones hypothesizes that the pathophysiology of radia-
tion-induced LS is the result of transient demyelination
[9]. He believes that radiation inhibits normal proliferation4 International Journal of Otolaryngology
1
2
2
1 2 5
5
4
3
6
1. Pyramidal tracts
2. Extrapyramidal tracts
3. Dorsal column-medial lemniscus system
4. Spinocerebellar tracts
5. Anterolateral system
6. Spinoolivary ﬁbers
∗ The anterolateral system is the spinothalamic tracts.
They are highlighted in gray.
Figure 3: Spinal cord anatomy. The anterior spinothalamic tracts
are hypothesized to be the target of IMRT-caused LS and are
highlighted in gray.
of oligodendroglial cells which produce myelin. Without
the myelin, the exposed sensory neurons become vulnerable
to irritation from neck ﬂexion causing electric-shock sen-
sations. Eventually, the oligodendroglial cells recover from
radiation, more myelin is produced, and the symptoms of LS
abate.
UsingIMRT,amuchdiﬀerentradiationdosedistribution
is delivered to the spinal cord than with non-IMRT opposed
lateral radiotherapy. Rather than a homogeneous dose
distributedthroughoutthecord,thereisadosegradientwith
most of the radiation delivered anteriorly. Figure 2 compares
the spinal cord dose distribution seen in our IMRT case
with the same patient if he were treated via a non-IMRT
opposed laterals technique. Butler et al. hypothesized that
the dorsal columns served as the radiation target leading
to LS [11]. Given the development of LS in our patient
and the more anterior radiation dose distribution seen with
IMRT, we suggest a more anterior spinal cord tract as the
target for IMRT-caused LS. As ﬁrst mentioned by Jones,
we hypothesize that irradiation of the spinothalamic tract,
which recognizes simple touch, pain, and temperature, is the
cause of LS for our patient (Figure 3).
4. Conclusion
Although intensity-modulated radiotherapy delivers a much
more conformal dose of radiation, its use in head and neck
cancer can still lead to the development of Lhermitte’s sign.
Given the predominantly anterior dose distribution with
IMRT, we suggest the spinothalamic tract to be the target of
IMRT-caused LS.
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